Blab Tech
Spectral AI Reports Q2 2026 Results, Receives FDA Clearance for DeepView Burn System
Spectral AI, Inc. (NASDAQ: MDAI), a Dallas‑based firm that builds artificial‑intelligence diagnostics for wound care, announced its second‑quarter 2026 financial results and disclosed that its DeepView System has earned FDA De Novo clearance for treating burns. The clearance, granted on May 26 2026, paves the way for the company to begin commercial distribution of the device in the United States by the end of the year.
The DeepView System merges multispectral imaging with a proprietary AI algorithm to deliver an objective, real‑time evaluation of a burn wound’s healing potential. In a press release, Spectral AI noted that the device was cleared under the FDA’s De Novo pathway, a classification that allows commercial sales once the product is marketed. The clearance marks a significant milestone for Spectral AI, which has been refining the technology since the early 2020s and has previously shown the system’s ability to detect non‑healing tissue in burn wounds.
Earlier in March 2026, the company secured $31.7 million in advanced funding from the Biomedical Advanced Research and Development Authority (BARDA) through Project BioShield. The grant is intended to accelerate development and procurement of the DeepView System. In addition, Spectral AI drew $6.5 million from an existing credit facility with Avenue Capital Group after the FDA clearance, providing non‑dilutive capital to strengthen its balance sheet.
Leadership and contract milestones were also highlighted. The firm appointed David McGuire as chief financial officer and Darcy Bajko as chief commercial officer in preparation for commercial activities. Spectral AI completed all remaining milestones under its Department of Defense contract for the DeepView handheld device, delivered a fully functioning prototype, and began a UK‑based study to expand the device’s label to include assessment of heads, hands, and feet.
Financially, the company reported a decline in research and development revenue to $3.5 million for Q2 2026, down from $5.1 million in the same period a year earlier. The drop reflects reduced reimbursed costs under the BARDA Project BioShield contract following FDA clearance and the completion of performance under the Department of Defense contract. Gross margin fell to 31.6 % from 45.2 % in the prior year, largely due to the cost‑share provisions of the BARDA contract and a lower margin on the fixed‑fee Department of Defense contract.
Operating expenses increased by 23.2 % to $5.4 million, driven by higher general and administrative costs from equity awards, a modest rise in selling and marketing spend ahead of commercial sales, and a small increase in research and development costs. Net loss for the quarter was $4.2 million, or $0.13 per share, compared with a $8.0 million loss ($0.31 per share) in the same period a year earlier. The company’s cash balance stood at $14.0 million as of June 30 2026, down from $15.4 million at the end of 2025.
Spectral AI reiterated its revenue guidance for the full year ending December 31 2026 at approximately $18.5 million. The guidance reflects continued development under the BARDA contract but does not include any material contribution from the anticipated commercial sales of the DeepView System for burn indication, which the company expects to begin by year‑end 2026.
The firm’s progress places it at the forefront of AI‑enabled wound assessment. The FDA clearance and BARDA funding provide regulatory and financial foundations for a commercial launch that could improve treatment decisions for burn patients. Spectral AI’s leadership changes and completed contract milestones signal a shift from development to commercialization. Upcoming activities include the first commercial sales in the United States, UKCA label expansion, and a planned Triage and Treatment Outcome Study in Q4 2026 to demonstrate clinical benefits.
At present, Spectral AI has secured regulatory approval, government funding, and capital to support its transition to commercial operations. The company’s next steps involve launching the DeepView System in the U.S. market, expanding its label in the U.K. and other regions, and conducting outcome studies to validate the device’s impact on patient care.
The DeepView System merges multispectral imaging with a proprietary AI algorithm to deliver an objective, real‑time evaluation of a burn wound’s healing potential. In a press release, Spectral AI noted that the device was cleared under the FDA’s De Novo pathway, a classification that allows commercial sales once the product is marketed. The clearance marks a significant milestone for Spectral AI, which has been refining the technology since the early 2020s and has previously shown the system’s ability to detect non‑healing tissue in burn wounds.
Earlier in March 2026, the company secured $31.7 million in advanced funding from the Biomedical Advanced Research and Development Authority (BARDA) through Project BioShield. The grant is intended to accelerate development and procurement of the DeepView System. In addition, Spectral AI drew $6.5 million from an existing credit facility with Avenue Capital Group after the FDA clearance, providing non‑dilutive capital to strengthen its balance sheet.
Leadership and contract milestones were also highlighted. The firm appointed David McGuire as chief financial officer and Darcy Bajko as chief commercial officer in preparation for commercial activities. Spectral AI completed all remaining milestones under its Department of Defense contract for the DeepView handheld device, delivered a fully functioning prototype, and began a UK‑based study to expand the device’s label to include assessment of heads, hands, and feet.
Financially, the company reported a decline in research and development revenue to $3.5 million for Q2 2026, down from $5.1 million in the same period a year earlier. The drop reflects reduced reimbursed costs under the BARDA Project BioShield contract following FDA clearance and the completion of performance under the Department of Defense contract. Gross margin fell to 31.6 % from 45.2 % in the prior year, largely due to the cost‑share provisions of the BARDA contract and a lower margin on the fixed‑fee Department of Defense contract.
Operating expenses increased by 23.2 % to $5.4 million, driven by higher general and administrative costs from equity awards, a modest rise in selling and marketing spend ahead of commercial sales, and a small increase in research and development costs. Net loss for the quarter was $4.2 million, or $0.13 per share, compared with a $8.0 million loss ($0.31 per share) in the same period a year earlier. The company’s cash balance stood at $14.0 million as of June 30 2026, down from $15.4 million at the end of 2025.
Spectral AI reiterated its revenue guidance for the full year ending December 31 2026 at approximately $18.5 million. The guidance reflects continued development under the BARDA contract but does not include any material contribution from the anticipated commercial sales of the DeepView System for burn indication, which the company expects to begin by year‑end 2026.
The firm’s progress places it at the forefront of AI‑enabled wound assessment. The FDA clearance and BARDA funding provide regulatory and financial foundations for a commercial launch that could improve treatment decisions for burn patients. Spectral AI’s leadership changes and completed contract milestones signal a shift from development to commercialization. Upcoming activities include the first commercial sales in the United States, UKCA label expansion, and a planned Triage and Treatment Outcome Study in Q4 2026 to demonstrate clinical benefits.
At present, Spectral AI has secured regulatory approval, government funding, and capital to support its transition to commercial operations. The company’s next steps involve launching the DeepView System in the U.S. market, expanding its label in the U.K. and other regions, and conducting outcome studies to validate the device’s impact on patient care.
